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Abstract
Background: Bariatric surgery is able to improve glucose and lipid metabolism, and cardiovascular
function in morbid obesity. Aim of this study was to compare the long-term effects of
malabsorptive (biliary pancreatic diversion, BPD), and restrictive (laparoscopic gastric banding,
LAGB) procedures on metabolic and cardiovascular parameters, as well as on metabolic syndrome
in morbidly obese patients.
Methods: 170 patients studied between 1989 and 2001 were called back after a mean period of
65 months. 138 patients undergoing BPD (n = 23) or LAGB (n = 78), and control patients (refusing
surgery and treated with diet, n = 37) were analysed for body mass index (BMI), blood glucose,
cholesterol, and triglycerides, blood pressure, heart rate, and ECG indexes (QTc, Cornell voltage-
duration product, and rate-pressure-product).
Results: After a mean 65 months period, surgery was more effective than diet on all items under
evaluation; diabetes, hypertension, and metabolic syndrome disappeared more in surgery than in
control patients, and new cases appeared only in controls. BPD was more effective than LAGB on
BMI, on almost all cardiovascular parameters, and on cholesterol, not on triglyceride and blood
glucose. Disappearance of diabetes, hypertension, and metabolic syndrome was similar with BPD
and with LAGB, and no new cases were observed.
Conclusion: These data indicate that BPD, likely due to a greater BMI decrease, is more effective
than LAGB in improving cardiovascular parameters, and similar to LAGB on metabolic parameters,
in obese patients. The greater effect on cholesterol levels is probably due to the different
mechanism of action.
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Obesity is often accompanied by diabetes, hyperlipi-
demia, arterial hypertension [1]; all are known risk factors
for cardiovascular (CV) diseases, i.e. accelerated athero-
sclerosis [2] and congestive heart failure [CHF, [3]]. Insu-
lin resistance [4], subclinical inflammation [5],
sympathetic overactivity [6], and endothelial dysfunction
[7], are present and often coexist in the same individual
[8]. These abnormalities are risk factors for the develop-
ment of left ventricular hypertrophy [LVH, [9,10]], which
is frequently detected in severe obesity, and is an alleged
risk factor for CHF [3,10]. The rate pressure product (RPP,
heart rate × systolic BP) is a correlate of myocardial oxygen
consumption, and hence of work load of the heart [11], is
raised in obesity [11-13]; RPP is considered a determinant
of cardiovascular risk, since its increase precedes ischemic
events [11].
Bariatric surgery improves glucose and lipid metabolism
[14,15] and attenuates endothelial dysfunction [16] and
sympathetic overactivity [17]. These changes are inter-
related, since reduction of sympathetic overactivity,
improvement of endothelial dysfunction, and decrease of
insulin resistance correlate each other, and with decreases
of body weight and of visceral fat [18]. In addition, bari-
atric surgery has been shown to prevent arterial hyperten-
sion [19] and diabetes mellitus [19-21].
Bariatric surgery has been reported to reduce LVM indices
in a number of studies, and has beneficial effects on virtu-
ally all sections of electrocardiogram (ECG)[22]. It is pos-
sible that weight loss is effective in reducing LVM if
accompanied by decrease of blood pressure [17]. LVM
correlates with circulating leptin levels [23], and with
insulin resistance [24], and decreases of LVM and of leptin
levels are correlated [23] in obese normotensive subjects.
The amount of weight loss is greater with malabsorptive
than with restrictive bariatric procedures [14,15,25]. Only
few studies have directly compared different techniques
[21,26-28], and were usually of short duration, and with-
out control patients, i.e. patients not undergoing surgery
[except for ref. [21]]. The aim of this study was to compare
the long-term effects of malabsorptive (biliary pancreatic
diversion, BPD], and restrictive (laparoscopic gastric
banding, LAGB) procedures on metabolic and cardiovas-
cular parameters, and on metabolic syndrome, in mor-
bidly obese patients.
Methods
Laparoscopic gastric banding (LAGB) and biliary pancre-
atic diversion (BPD) are routinely performed at participat-
ing Institutions, following the indications and guidelines
of NIH [29]; procedures have been approved by local eth-
ics committees; patients undergo preliminary clinical
work-up including psychological and psychiatric evalua-
tion [14].
The protocol of this study, i.e. ad-hoc call-back of patients
for selected determinations, was specifically approved by
local ethics committees, and all participating patients gave
written informed consent. Patients undergoing surgery
between 1989 and 2001 were considered in this study; all
patients agreeing to come back to Institutions were con-
sidered; they were interviewed about current therapies,
and underwent anthropometric evaluation, ECG record-
ing, and heart rate and blood pressure measurement, fast-
ing blood sampling for glucose and lipid determination.
Patients who refused surgery and agreed to be followed-
up (controls), were also considered. They were treated
with diet [14]. Patients with atrial fibrillation or left bun-
dle branch block were excluded, as well as patients receiv-
ing drugs known to interfere with electrophysiological
ECG conduction. Therefore, a total number of 32 patients
could not be included in the study because of the above
clinical conditions or because basal ECG paper tracings
had vanished and become unreadable; these patients were
not different from the remaining 138 patients as to base-
line characteristics or to clinical and metabolic follow-up.
Blood sampling [14,15] and ECG tracing in all patients
was carried out at rest, after an overnight fast. On the same
occasion, arterial blood pressure was evaluated by the
same physician, using the same sphygmomanometer with
an appropriate cuff.
Outcome measures
Arterial hypertension was diagnosed when systolic/diasto-
lic blood pressure was ≥ 140/90 mmHg, or when subjects
were under antihypertensive treatment. Diabetes mellitus
was diagnosed when fasting blood glucose levels were >
126 mg/dl, or when subjects were under antihyperglyc-
emic treatment (metformin). Rate pressure product (RPP,
mmHg × bpm × 10-2) was calculated, and was used as an
index of myocardial oxygen consumption and hence of
work load of the heart [11]. Diagnosis of metabolic syn-
drome was established according to the ATP III criteria
[30], and included three or more components.
Interviews and anthropometry
Patients were interviewed as to current and past therapies,
and were measured for height and weight, to calculate
body mass index, as already reported [14,15].
ECG: QTc interval, Cornell voltage-duration product
All individual ECGs performed at baseline and at follow-
up were compared by one person (ML). QT intervals were
measured manually from the onset of the interval
between Q and S waves of the electrocardiogram to the
end of the T wave on the isoelectric baseline, and cor-
rected according to Bazett's formula (QTc = QT/√RR) [31].Page 2 of 7
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was excluded from analysis [32]. QT interval was meas-
ured in at least 10 leads in each subject. Through ECG
reading (paper running at 25 mm/s, 1 mm/mV), the Cor-
nell voltage-duration product was calculated:
[(RaVL+SV3) × QRS] in mm.ms, with an adjustment of 6
mm in women. These composite ECG criteria detect LVH
with about 95% specificity in healthy and in hypertensive
subjects [33-35], and this approach allows direct evalua-
tion of LVM [36-38].
Statistical analysis
Inter-group comparisons were performed by one way
analysis of variance (ANOVA) followed by Scheffè's mul-
tiple comparison test. Intra-group comparisons were per-
formed by two-tailed Student's t test for paired samples.
Since a normal distribution of data was not assured, non-
parametric tests (Mann-Whitney and Wilcoxon test) were
also used. Absolute frequencies and changes of comorbid-
ities were compared by χ2 test. Pairwise correlations were
computed between changes of clinical conditions (inde-
pendent variables) and change of Cornell voltage-dura-
tion product, and of RPP (dependent variables). Next, a
multivariate regression analysis was carried out to assess
the role of independent variables significant at univariate
analysis (plus age and sex) in change of clinical conditions
such as diabetes mellitus, arterial hypertension, and met-
abolic syndrome, and changes of Cornell voltage-dura-
tion product, and of RPP; we reported significance of the
whole model, plus F and p of variables statistically signif-
icant at multivariate regression analysis. p levels < 0.05
were considered statistically significant.
Results
Figure 1 shows decrease of BMI in patients undergoing
surgery and in control patients: weight loss was greater
with BPD than with LAGB, and greater with LAGB than in
controls, at virtually all time intervals. Table 1 shows that
surgery, whether BPD or LAGB, was significantly superior
to traditional treatment on all parameters considered.
Diabetes mellitus and arterial hypertension disappeared
in a few surgery patients, and appeared in a few control
patients. Patients with type 2 diabetes mellitus differed
from other patients only for older age and for greater
decrease of blood glucose levels. Table 2 shows the effects
of BPD and of LAGB on metabolic and cardiovascular
parameters. BPD was statistically more effective on weight
loss, on decrease of systolic and diastolic blood pressure,
and on decrease of Cornell voltage-duration product and
of RPP, and hence on reduction of cases of LVH. BPD, at
difference from LAGB was also effective in decreasing cho-
lesterol levels, while the effect on blood glucose and on
triglycerides, and on disappearance of metabolic syn-
drome, was not different.
In surgery patients, decrease of systolic and diastolic
blood pressure, of Cornell voltage-duration product, of
RPP correlated with decrease of BMI. The decrease of cho-
lesterol was greater with BPD than with LAGB, independ-
ent of initial BMI, and of the amount of weight loss (not
shown), and therefore seems due to the kind of surgery
rather than to the amount of weight loss.
At multiple regression analysis disappearance of diabetes
mellitus was significantly associated with presence of dia-
Table 1: Clinical, ECG, and metabolic details of patients in the study (controls and patients undergoing surgery).
CONTROLS SURGERY
BEFORE AFTER CHANGE BEFORE AFTER CHANGE
N (men, women) 37 (5/32) 101 (17/84)
Age (y) 46.5 ± 2.07 44.8 ± 0.98
Interval (mos) 59.3 ± 4.44 65.4 ± 4.65
BMI (kg/m2) 43.8 ± 1.18 43.5 ± 1.54 +0.3 ± 0.81 45.7 ± 0.67 34.2 ± 0.59 # -11.1 ± 0.71 #
Systolic BP (mmHg) 133.5 ± 2.39 140.5 ± 3.12 +7.0 ± 3.82 136.4 ± 1.65 127.1 ± 1.48 # -9.4 ± 1.95 #
Diastolic BP (mmHg) 83.7 ± 1.52 89.4 ± 1.91 +5.8 ± 2.46 85.9 ± 1.34 81.1 ± 1.01 # -4.7 ± 1.53 #
Hypertension (y/n) 14/23 21/16 +7 (-3, +10) 40/61 20/81 # -20 (-23, +3) §
Heart rate (bpm) 74.9 ± 1.83 74.2 ± 1.84 -0.6 ± 2.31 80.4 ± 1.29 * 67.5 ± 0.98 # -12.9 ± 1.24 #
QTc (msec) 412.8 ± 4.62 410.7 ± 4.88 -2.1 ± 5.41 412.4 ± 2.99 398.7 ± 2.81 * -13.7 ± 3.03 *
Cornell-voltage (mm.ms) 1487.3 ± 84.75 1434.6 ± 81.64 -52.7 ± 62.43 1561.1 ± 57.77 1461.3 ± 57.39 -106.1 ± 59.44
RPP 99.7 ± 2.99 104.7 ± 3.91 +5.6 ± 4.43 109.7 ± 2.39 * 86.2 ± 1.58 # -23.6 ± 2.42 #
LVH (y/n) ° 8/29 5/32 -3 (+2, -5) 31/70 28/73 -3 (+9, -12)
Cholesterol (mg/dl) 195.4 ± 8.66 198.9 ± 6.88 +2.1 ± 5.17 203.5 ± 4.47 183.5 ± 5.82 -20.4 ± 6.55 *
Triglycerides (mg/dl) 114.1 ± 8.57 123.9 ± 8.96 +9.4 ± 8.04 162.4 ± 17.13 100.3 ± 5.84 * -64.1 ± 17.14 *
Blood glucose (mg/dl) 117.7 ± 8.74 124.6 ± 9.63 +6.9 ± 6.77 106.2 ± 3.58 91.1 ± 1.91 # -15.1 ± 3.18 **
Diabetes mellitus (y/n) 9/28 11/26 +2 14/87 4/97 # -10 *
Metabolic Syndrome (y/n) 15/22 13/24 -2 (-6, +4) 30/71 11/90 ** -19 *
Means ± SE or absolute frequencies
° as defined by ECG criteria
* = p < 0.05; ** = p < 0.01; # = p < 0.001 vs corresponding values of controlsPage 3 of 7
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0.0001); disappearance of arterial hypertension was asso-
ciated (model r = .562, p = 0.0001) with presence of
hypertension at the beginning (F = 24.415, p = 0.0001)
and change of BMI (F = 10.138, p = 0.02); disappearance
of metabolic syndrome was associated (model r = .763, p
= 0.0001) with presence of metabolic syndrome at the
beginning (F = 53.589, p = 0.0001) and with change of
BMI (F = 6.739, p = 0.0115). Table 3 shows that change of
Cornell voltage-duration product correlated with initial
Cornell voltage-duration product, with change of blood
pressure and of BMI; at multiple regression analysis, the
model accounted for r = .635, and only initial Cornell
voltage-duration product, and change of systolic BP corre-
lated with change of Cornell voltage-duration product.
Table 3 also shows that change of RPP correlated with ini-
tial RPP, HR and blood pressure, and with change of
systolic blood pressure, of heart rate, and of BMI; at mul-
tiple regression analysis, the model accounted for r = .995,
and initial RPP, HR and BP, and change of HR and of
systolic BP correlated with change of RPP.
Discussion
BPD is known to induce a greater weight loss than LAGB,
independently of initial BMI; this information comes
from a meta-analysis [25] and from two comparative
studies [27,28]. This finding was confirmed in the present
study. Surgery was clearly more effective than control
treatment, as already reported in the only study including
control patients [21]. The pattern of BMI depicted in Fig-
ure 1 indicates that our findings were representative of
what happens with the two surgical procedures. In agree-
ment with two small studies [27,28], the effect on meta-
bolic variables, and the disappearance of diabetes mellitus
(patients were treated with metformin, when required)
were not different for the 2 procedures. Also disappear-
ance of metabolic syndrome was not different. As to met-
abolic effects, the only difference was in cholesterol
decrease, which appears more due to the technique than
to amount of weight loss. We have other data [39] show-
Table 2: Clinical, ECG, and metabolic details of patients undergoing biliary-pancreatic-diversion (BPD) and laparoscopic gastric 
banding (LAGB).
BPD LAGB
BEFORE AFTER CHANGE BEFORE AFTER CHANGE
N (men, women) 23 (7/16) 78 (10/68)
Age (y) 45.3 ± 1.78 44.2 ± 1.16
BMI (kg/m2) 48.6 ± 1.45 30.1 ± 1.26 -18.5 ± 1.43 44.8 ± 0.74 * 35.4 ± 0.61 # -9.5 ± 0.66 #
Systolic BP (mmHg) 148.3 ± 4.98 121.7 ± 2.86 -26.5 ± 5.16 132.9 ± 1.35 # 128.6 ± 1.69 * -4.3 ± 1.61 #
Diastolic BP (mmHg) 97.8 ± 3.81 76.3 ± 1.92 -21.5 ± 3.35 82.4 ± 1.04 # 82.6 ± 1.12 * +0.1 ± 1.26 #
Hypertension (y/n) 12/11 1/22 -11 28/50 19/59 -9 (-12, + 3)
Heart rate (bpm) 82.4 ± 3.63 69.8 ± 2.22 -12.6 ± 2.98 79.8 ± 1.31 66.8 ± 1.09 -13.0 ± 1.36
QTc (msec) 403.5 ± 5.44 388.9 ± 6.27 -14.6 ± 5.83 415.1 ± 3.48 401.6 ± 3.09 -13.5 ± 3.54
Cornell-voltage (mm.ms) 1612.6 ± 155.48 1249.6 ± 144.63 -391.4 ± 172.87 1545.9 ± 59.69 1523.8 ± 59.62 -22.2 ± 54.97 **
RPP 122.9 ± 7.79 85.4 ± 3.84 -37.5 ± 6.96 105.9 ± 1.92 * 86.4 ± 1.71 -19.5 ± 2.19 **
LVH (y/n) ° 8/15 2/21 -6 23/55 26/52 +3 (-6, +9) *
Cholesterol (mg/dl) 210.1 ± 9.78 133.8 ± 6.43 -76.3 ± 11.48 200.5 ± 4.75 205.8 ± 5.26 # +5.3 ± 3.82 #
Triglycerides (mg/dl) 190.4 ± 45.58 83.3 ± 7.02 -107.0 ± 48.33 149.6 ± 12.32 108.1 ± 7.69 * -41.4 ± 10.31
Blood glucose (mg/dl) 98.8 ± 7.66 82.1 ± 2.13 -16.7 ± 6.94 108.4 ± 4.04 93.7 ± 2.31 ** -14.7 ± 3.49
Diabetes mellitus (y/n) 2/21 0/23 -2 12/66 4/74 -8
Metabolic Syndrome (y/n) 5/18 0/23 -5 25/53 11/67 -14
Means ± SE or absolute frequencies.
° as defined by ECG criteria
* = p < 0.05; ** = p < 0.01; # = p < 0.001 vs corresponding values of BPD
Decrease of body mass index (BMI, kg/m2) in patients under-going BPD, LAGB, and in control patientsFigure 1
Decrease of body mass index (BMI, kg/m2) in patients 
undergoing BPD, LAGB, and in control patients. 
Means ± SE. at all times intervals, BMI decrease was signifi-
cantly greater with BPD than with LAGB (°, p < 0.05 or less), 
and with LAGB than in controls (*, p < 0.05 or less).
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nal-By-Pass) is more effective than LAGB in reducing
cholesterol levels. The cholesterol level reduction that we
and others have reported is a quite dramatic phenomenon
and is likely due to the major reduction in bile acid re-
absorption in the intestine and possibly to altered regula-
tion of the feedback mechanisms controlled by nuclear
protein such as LXR, FXR and PPAR; these transcriptional
factors are involved in bile acid and cholesterol metabo-
lism, occurring in patients undergoing BPD (which causes
malabsorption and also reduced bile re-absorption), but
not LAGB (a purely restrictive bariatric proce-
dure)[14,18,19,40-42]. It is also possible that reduced
gastric volume and reduced production of gastric lipase,
as well as reduced secretion of colecystokinin (that physi-
ologically stimulates digestive enzyme secretion such as
lipases and proteases) might result in a marked decrease
in the hydrolysis of triacylglycerols, with a reduction of
the absorption of free fatty acids [43].
Some cardiovascular parameters were more influenced by
BPD than by LAGB, such as diastolic and systolic blood
pressure, Cornell voltage-duration product and RPP. It
seems that this was generally due to a greater effect on
BMI, although a direct role of BMI in multiple regression
analysis was not evident.
Bariatric surgery is known to improve all sections of ECG
[22]; ECG has been used as a method of measuring LVM
(Cornell voltage-duration product) and of assessing work
load [RPP, [11,33-38]]. In this study we found that BPD is
superior to LAGB on these parameters. The fact that
change of Cornell voltage-duration product is dependent
first at all on its initial value fully agrees with the findings
that decrease of LVM (echocardiographic measures) is
dependent first at all with initial LVM [22]; in a previous
paper we have shown that Cornell voltage-duration prod-
uct and echocardiographic measures similarly describe
decrease of LVM after weight loss, correlated with decrease
of leptin levels [23]. Obesity is often accompanied, espe-
cially when of long duration, by increase of LVM [22];
probably, when obesity is untreated, the natural trend is
of a progressive increase of LVM. Weight loss can reduce
LVM [13,17,22], especially if accompanied by reduction
of blood pressure [17]. In this study we found a significant
reduction of Cornell voltage-duration product together
with a significant decrease of both diastolic and systolic
blood pressure. This finding corroborates a previous study
from this group showing that weight loss alone is not suf-
ficient to allow decrease of LVM [17].
HR and QTc are assumed as an index of sympathetic over-
activity [17]; their decrease after weight loss is well in
agreement with a previous study showing enhanced para-
sympathetic activity after diet-induced weight loss [44].
Rate pressure product, a correlate of myocardial oxygen
consumption, and hence of work load of the heart
[11,12], decreased with weight loss. This finding has never
been published before. Decrease of RPP correlated with
initial RPP as well as with decrease of BMI, and of diastolic
BP. Given the value of RPP and of heart rate as determi-
nants of cardiovascular risk [11,45,46], these data indicate
Table 3: Linear and multiple regression
Linear Regression Multiple Regression
A
Δ Cornell Voltage Product Model r = .635,
Δ BMI .204, 0.0406
Cornell voltage product initial .516, 0.0001 F = 45.471, 0.0001
Δ Systolic BP .282, 0.0001 F = 9.616, 0.01
Δ Diastolic BP .235, 0.0001
B
Δ RPP Model r = .989,
Δ BMI .297, 0.0025
RPP initial .786, 0.0001 F = 158.97, 0.0001
Systolic BP .491, 0.0001 F = 93.45, 0.0001
Diastolic BP .387, 0.0001
HR .616, 0.0001 F = 110.42, 0.0001
Δ HR .754, 0.0001 F = 1721.69, 0.0001
Δ Systolic BP .685, 0.0001 F = 1060.15, 0.0001
Δ Diastolic BP .489, 0.0001
A. On the left: correlations (linear regression) between changes of Cornell voltage product (dependent variable) and changes of clinical variables 
(independent variables): r and p are indicated. On the right, multiple regression model, partial F and p of independent variables statistically 
significant. B. On the left: correlations (linear regression) between changes of RPP (dependent variable) and changes of clinical variables 
(independent variables): r and p are indicated. On the right, multiple regression model, partial F and p of independent variables statistically 
significant.Page 5 of 7
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of importance in reducing the overall cardiovascular risk
in morbid obesity.
Conclusion
These data indicate that BPD, likely due to a greater BMI
decrease, is more effective than LAGB in improving cardi-
ovascular parameters, and similar to LAGB on metabolic
parameters, in obese patients. The greater effect on choles-
terol levels is probably due to the different mechanism of
action.
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